{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:28:20Z","timestamp":1780435700438,"version":"3.54.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Extramammary Paget disease (EMPD) is a rare form of cutaneous, intraepithelial adenocarcinoma, which typically presents itself as an erythematous plaque originating from apocrine-gland rich regions, such as the vulva, the perianal region, the scrotum, the penis, or the axilla. EMPD patients typically have a good prognosis, with expected 5-year survival of 60%\u201392%, but it is estimated that about one-third of EMPD patients will develop lymph node or distant metastases. Treatment approaches for EMPD include locoregional therapies such as broad surgical resection, radiotherapy, or topical imiquimod, when the disease is localized, and chemotherapy and biological agents for advanced EMPD. We report the case of a 58-year-old man diagnosed with locally advanced, symptomatic HER2-overexpressing, AR-positive EMPD, who achieved long-term tumor control with a sequence of several trastuzumab-based treatments (more than 30 months with second-line carboplatin plus paclitaxel plus trastuzumab followed by trastuzumab maintenance; 9 months for third-line vinorelbine plus trastuzumab). Even if it is reported that AR expression occurs concomitantly with HER2 overexpression in more than half of the cases of EMPD, to the best of our knowledge, this is the first case report describing androgen receptor blockade therapy in combination with an anti-HER2 agent. Our patient did not benefit from androgen receptor blockade in combination with trastuzumab, thus suggesting that AR expression may simply reflect an intrinsic characteristic of the EMPD cell of origin, rather than tumor dependence upon AR signaling. Given the reported sensibility to anti-HER2 therapy, also new antibody drug conjugates targeting HER2 are worth exploring in the management of advanced EMPD.<\/jats:p>","DOI":"10.3389\/fonc.2022.925551","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T04:40:37Z","timestamp":1660797637000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin"],"prefix":"10.3389","volume":"12","author":[{"given":"Emma","family":"Zattarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ligorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lobefaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Fuc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Peverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vingiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia V.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Capri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.01.032","article-title":"Treatment outcomes in a large cohort of patients with invasive extramammary paget's disease","volume":"125","author":"Karam","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2011.12.008","article-title":"Invasive extramammary paget's disease and the risk for secondary tumours in Europe","volume":"38","author":"van der Zwan","year":"2012","journal-title":"Eur J Surg Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/srep44933","article-title":"Tumor wide horizontal invasion predicts local recurrence for scrotal extramammary paget's disease","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e328360df63","article-title":"Primary cutaneous vulvar extramammary paget's disease involving the endocervix and detected by pap smear","volume":"45","author":"Westacott","year":"2013","journal-title":"Pathol 06"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002064","article-title":"Extramammary paget disease: A review of the literature-part I: History, epidemiology, pathogenesis, presentation, histopathology, and diagnostic work-up","volume":"46","author":"Morris","year":"2020","journal-title":"Dermatol Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01114","article-title":"Clinical characteristics, treatment, and prognostic factors of patients with primary extramammary paget's disease (EMPD): A retrospective analysis of 44 patients from a single center and an analysis of data from the surveillance, epidemiology, and end results (SEER) database","volume":"10","author":"Weng","year":"2020","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.hoc.2018.09.003","article-title":"Extramammary paget's disease","volume":"33","author":"Asel","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.06.004","article-title":"A proposal for a TNM staging system for extramammary paget disease: Retrospective analysis of 301 patients with invasive primary tumors","volume":"83","author":"Ohara","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00204","article-title":"Case of metastatic extramammary paget disease of the vulva treated successfully with trastuzumab emtansine","volume":"2","author":"Hsieh","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10121040","article-title":"Hormonal environment and HER2 status in extra-mammary paget's disease (eMPD): A systematic literature review and meta-analysis with clinical considerations","volume":"10","author":"Angelico","year":"2020","journal-title":"Diagn (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2015.07.007","article-title":"Androgen receptor, androgen-producing enzymes and their transcription factors in extramammary paget disease","volume":"46","author":"Azmahani","year":"2015","journal-title":"Hum Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780153","article-title":"Expression of structurally unaltered androgen receptor in extramammary paget's disease","volume":"80","author":"Fujimoto","year":"2000","journal-title":"Lab Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1309\/P756-XXCB-TV71-U4XV","article-title":"Extramammary paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor","volume":"113","author":"Diaz de Leon","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-014-0686-2","article-title":"Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary paget's disease","volume":"20","author":"Tokuda","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13200","article-title":"Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary paget's disease","volume":"43","author":"Yoshino","year":"2016","journal-title":"J Dermatol Jun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13693","article-title":"Achieved good response of s-1 and docetaxel combination chemotherapy in two patients with metastatic extramammary paget's disease","volume":"44","author":"Egashira","year":"2017","journal-title":"J Dermatol May"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol 04 01"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000333002","article-title":"A case of metastatic extramammary paget's disease responding to trastuzumab plus paclitaxel combination therapy","volume":"3","author":"Hanawa","year":"2011","journal-title":"Case Rep Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/401362","article-title":"Dramatic clinical response of relapsed metastatic extramammary paget's disease to trastuzumab monotherapy","volume":"2012","author":"Wakabayashi","year":"2012","journal-title":"Case Rep Dermatol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9769-8","article-title":"Gene expression profiling guiding diagnosis and therapy of rare mammary-like anogenital gland carcinomas","volume":"29","author":"Gunv\u00e9n","year":"2012","journal-title":"Med Oncol Mar"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/895151","article-title":"Metastatic extramammary paget's disease of scrotum responds completely to single agent trastuzumab in a hemodialysis patient: Case report, molecular profiling and brief review of the literature","volume":"2015","author":"Barth","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1422","article-title":"Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary paget's disease: A case report and review of the literature","volume":"7","author":"Ichiyama","year":"2017","journal-title":"Mol Clin Oncol Nov"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.9930","article-title":"Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary paget's disease","volume":"17","author":"Lu","year":"2019","journal-title":"Oncol Lett Mar"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27272","article-title":"Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2","volume":"10","author":"Nordmann","year":"2019","journal-title":"Oncotar Nov 19"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001771","article-title":"Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary paget's disease of the vulva","volume":"30","author":"Bartoletti","year":"2020","journal-title":"Int J Gynecol Cancer 11"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15096","article-title":"Case of metastatic extramammary paget's disease treated with trastuzumab-biosimilar monotherapy after s-1 and docetaxel combination chemotherapy","volume":"47","author":"Kimura","year":"2020","journal-title":"J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06865.x","article-title":"Androgen-deprivation regimen for multiple bone metastases of extramammary paget disease","volume":"153","author":"Yoneyama","year":"2005","journal-title":"Br J Dermatol Oct"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.5227\/skincancer.16.247","article-title":"Total androgen blockade therapy for an advanced case of extramammary paget's carcinoma","author":"Shirasaki","year":"2001","journal-title":"Skin Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical Oncology\/College of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00038","article-title":"Metastatic extramammary paget's disease: Pathogenesis and novel therapeutic approach","volume":"8","author":"Fukuda","year":"2018","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in","volume":"386","author":"Li","year":"2022","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27247","article-title":"Extramammary paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer\/testis antigens NY-ESO-1 and MAGE-a","volume":"10","author":"Pourmaleki","year":"2019","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1159\/000514345","article-title":"Treatment of metastatic extramammary paget disease with combination ipilimumab and nivolumab: A case report","volume":"14","author":"Guercio","year":"2021","journal-title":"Case Rep Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800437","article-title":"Androgen receptors are frequently expressed in mammary and extramammary paget's disease","volume":"18","author":"Liegl","year":"2005","journal-title":"Mod Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2008.01087.x","article-title":"Differential expression of mucin core proteins and keratins in apocrine carcinoma, extramammary paget's disease and apocrine nevus","volume":"36","author":"Miyamoto","year":"2009","journal-title":"J Cutan Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.925551\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T04:40:39Z","timestamp":1660797639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.925551\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":38,"alternative-id":["10.3389\/fonc.2022.925551"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.925551","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"article-number":"925551"}}